Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
Total Valuation
GeneDx Holdings has a market cap or net worth of $2.87B. The enterprise value is $2.13B.
Market Cap$2.87B
Enterprise Value$2.13B
Share Statistics
GeneDx Holdings has 28.07M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28.07M
Owned by Insiders61.07%
Owned by Instutions0.53%
Financial Efficiency
GeneDx Holdings’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -6.27%.
Return on Equity (ROE)-21.32%
Return on Assets (ROA)-12.47%
Return on Invested Capital (ROIC)-6.27%
Return on Capital Employed (ROCE)-6.37%
Revenue Per Employee$305,450
Profits Per Employee-$52,286
Employee Count1,000
Asset Turnover0.73
Inventory Turnover10.43
Valuation Ratios
The current PE Ratio of GeneDx Holdings is -39.53. GeneDx Holdings’s PEG ratio is 0.54.
PE Ratio-39.53
PS Ratio6.77
PB Ratio8.43
Price to Fair Value8.43
Price to FCF-60.81
Price to Operating Cash Flow-72.53
PEG Ratio0.54
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $305.45M and earned -$52.29M in profits. Earnings per share was -$1.99.
Revenue$305.45M
Gross Profit$185.56M
Operating Income-$22.12M
Pretax Income-$52.60M
Net Income-$52.29M
EBITDA-30.07M
Earnings Per Share (EPS)-1.99
Cash Flow
In the last 12 months, operating cash flow was -$28.50M and capital expenditures -$5.49M, giving a free cash flow of -$33.99M billion.
Operating Cash Flow-$28.50M
Free Cash Flow-$33.99M
Free Cash Flow per Share-$1.21
Dividends & Yields
GeneDx Holdings pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-1.64%
Earnings Yield-2.53%
Stock Price Statistics
Beta1.48
52-Week Price Change890.35%
50-Day Moving Average91.84
200-Day Moving Average64.96
Relative Strength Index (RSI)52.30
Average Volume (3m)753.88K
Important Dates
GeneDx Holdings upcoming earnings date is Apr 30, 2025, After Close.
Last Earnings DateFeb 18, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
GeneDx Holdings as a current ratio of 3.61, with Debt / Equity ratio of 0.26
Current Ratio3.61
Quick Ratio3.42
Debt to Market Cap0.03
Net Debt to EBITDA0.90
Interest Coverage Ratio7.66
Taxes
In the past 12 months, GeneDx Holdings has paid -$319.00K in taxes.
Income Tax-$319.00K
Effective Tax Rate0.65%
Enterprise Valuation
GeneDx Holdings EV to EBITDA ratio is -88.14, with an EV/FCF ratio of -60.20.
EV to Sales6.70
EV to EBITDA-88.14
EV to Free Cash Flow-60.20
EV to Operating Cash Flow-71.80
Balance Sheet
GeneDx Holdings has $141.19M in cash and marketable securities with $64.25M in debt, giving a net cash position of -$76.93M billion.
Cash & Marketable Securities$141.19M
Total Debt$64.25M
Net Cash-$76.93M
Net Cash Per Share-$2.74
Tangible Book Value Per Share$3.22
Margins
Gross margin is 63.64%, with operating margin of -7.60%, and net profit margin of -17.12%.
Gross Margin63.64%
Operating Margin-7.60%
Pretax Margin-17.23%
Net Profit Margin-17.12%
EBITDA Margin-7.60%
EBIT Margin-18.22%
Analyst Forecast
The average price target for GeneDx Holdings is $113.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$113.17
Price Target Upside18.54%
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast50.79%
EPS Growth Forecast73.57%